跳至主要内容
临床试验/NCT00402740
NCT00402740已完成不适用

Protected Carotid Artery Stenting in Subjects at High Risk for Carotid Endarterectomy (CEA)

Abbott Medical Devices75 个研究点 分布在 1 个国家目标入组 322 人开始时间: 2006年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
322
试验地点
75
主要终点
Kaplan-Meier Estimate of Freedom From the Composite of Any Death, Stroke and MI During the 30 Day Post Procedural Period (DSMI), Plus Fatal and Non-fatal Ipsilateral Stroke From 31-365 Days and Annually Thereafter for a Total of 3 Years.

研究概览

简要总结

The purpose of this study is to evaluate the long-term safety and efficacy of the Xact™ Rapid Exchange Carotid Stent System used in conjunction with the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5) and the Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3), in the treatment of atherosclerotic carotid artery disease in high-surgical risk subjects.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Kaplan-Meier Estimate of Freedom From the Composite of Any Death, Stroke and MI During the 30 Day Post Procedural Period (DSMI), Plus Fatal and Non-fatal Ipsilateral Stroke From 31-365 Days and Annually Thereafter for a Total of 3 Years.

时间窗: 3 years

Freedom from DSMI to 30 days or ipsilateral stroke from 31 days to 3 years. KM event free (%) curve.

次要结局

  • Kapan-Meier Estimate of Freedom From Clinically Driven Target Lesion Revascularization Through Three Years.(3 years)
  • Acute Device Success(Post-procedure)
  • Procedural Success(30 Days)
  • Composite of Any Transient Ischemic Attack (TIA) and Amaurosis Fugax(≤30 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (75)

Loading locations...

相似试验